您的位置: 首页 > 农业专利 > 详情页

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
专利权人:
Bristol-Myers Squibb Company
发明人:
John P. Cogswell,Stacie M. Goldberg,Ashok K. Gupta,Maria Jure-Kunkel,Xi-Tao Wang,Jon M. Wigginton
申请号:
US14950748
公开号:
US10072082B2
申请日:
2015.11.24
申请国别(地区):
US
年份:
2018
代理人:
摘要:
The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充